Cargando…

Results of an early access treatment protocol of daratumumab in United States patients with relapsed or refractory multiple myeloma

BACKGROUND: Daratumumab is a human CD38‐directed monoclonal antibody indicated for the treatment of relapsed and refractory multiple myeloma (MM). METHODS: A multicenter, open‐label treatment protocol provided early access to daratumumab for patients who had progressive MM after they received ≥3 pri...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chari, Ajai, Lonial, Sagar, Mark, Tomer M., Krishnan, Amrita Y., Stockerl‐Goldstein, Keith E., Usmani, Saad Z., Londhe, Anil, Etheredge, Delores, Fleming, Sarah, Liu, Baolian, Ukropec, Jon, Lin, Thomas S., Jagannath, Sundar, Nooka, Ajay K.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2018
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6587745/ https://www.ncbi.nlm.nih.gov/pubmed/30395359 http://dx.doi.org/10.1002/cncr.31706

Ejemplares similares

Subcutaneous daratumumab and hyaluronidase-fihj in newly diagnosed or relapsed/refractory multiple myeloma
por: Sanchez, Larysa, et al.
Publicado: (2021)

Split First Dose Administration of Intravenous Daratumumab for the Treatment of Multiple Myeloma (MM): Clinical and Population Pharmacokinetic Analyses
por: Xu, Xu Steven, et al.
Publicado: (2020)

Relapsed and refractory lymphoid neoplasms and multiple myeloma with a focus on carfilzomib
por: Nooka, Ajay, et al.
Publicado: (2013)

Teclistamab versus real-world physician’s choice of therapy in triple-class exposed relapsed/refractory multiple myeloma
por: Krishnan, Amrita, et al.
Publicado: (2023)

Proteasome inhibition and its therapeutic potential in multiple myeloma
por: Chari, Ajai, et al.
Publicado: (2010)

Daratumumab, lenalidomide, and dexamethasone in relapsed/refractory myeloma: a cytogenetic subgroup analysis of POLLUX
por: Kaufman, Jonathan L., et al.
Publicado: (2020)

Evaluation of Sustained Minimal Residual Disease Negativity With Daratumumab-Combination Regimens in Relapsed and/or Refractory Multiple Myeloma: Analysis of POLLUX and CASTOR
por: Avet-Loiseau, Hervé, et al.
Publicado: (2021)

Eliminating the monitoring period with subcutaneous daratumumab: a single-center experience
por: Maples, Kathryn T., et al.
Publicado: (2023)

Influence of Disease and Patient Characteristics on Daratumumab Exposure and Clinical Outcomes in Relapsed or Refractory Multiple Myeloma
por: Yan, Xiaoyu, et al.
Publicado: (2017)

The outcomes of newly diagnosed elderly multiple myeloma patients treated at a single U.S. institution
por: Bonomo, Lauren, et al.
Publicado: (2016)

Potential role of daratumumab in the treatment of multiple myeloma
por: Khagi, Yulian, et al.
Publicado: (2014)

Daratumumab, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma: subgroup analysis of CASTOR based on cytogenetic risk
por: Weisel, Katja, et al.
Publicado: (2020)

Daratumumab-based regimens are highly effective and well tolerated in relapsed or refractory multiple myeloma regardless of patient age: subgroup analysis of the phase 3 CASTOR and POLLUX studies
por: Mateos, Maria-Victoria, et al.
Publicado: (2020)

Daratumumab plus lenalidomide/bortezomib/dexamethasone in Black patients with transplant-eligible newly diagnosed multiple myeloma in GRIFFIN
por: Nooka, Ajay K., et al.
Publicado: (2022)

PB2013: TECLISTAMAB COMPARED WITH REAL-WORLD THERAPIES IN PATIENTS WITH TRIPLE-CLASS EXPOSED RELAPSED/REFRACTORY MULTIPLE MYELOMA
por: Krishnan, A., et al.
Publicado: (2022)

Daratumumab-induced transient myopic shift
por: Mavrommatis, Maria A., et al.
Publicado: (2018)

P907: CARFILZOMIB, DEXAMETHASONE, AND DARATUMUMAB (KDD) VS CARFILZOMIB AND DEXAMETHASONE (KD) IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): FRAILTY SUBGROUP ANALYSIS OF THE CANDOR STUDY
por: Quach, H., et al.
Publicado: (2022)

Exposure‐Response and Population Pharmacokinetic Analyses of a Novel Subcutaneous Formulation of Daratumumab Administered to Multiple Myeloma Patients
por: Luo, Man (Melody), et al.
Publicado: (2020)

PB2132: EXCALIBER-RRMM: A PHASE 3, TWO-STAGE STUDY OF IBERDOMIDE, DARATUMUMAB, AND DEXAMETHASONE VERSUS DARATUMUMAB, BORTEZOMIB, AND DEXAMETHASONE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA
por: Lonial, Sagar, et al.
Publicado: (2023)

Daratumumab, carfilzomib, and dexamethasone in relapsed or refractory myeloma: final analysis of PLEIADES and EQUULEUS
por: Moreau, Philippe, et al.
Publicado: (2023)

P972: INDIRECT COMPARISON OF TECLISTIMAB IN MAJESTEC-1 VERSUS PHYSICIAN’S CHOICE OF THERAPY IN LONG-TERM FOLLOW-UP OF TRIPLE-CLASS EXPOSED RELAPSED/REFRACTORY MULTIPLE MYELOMA IN DARATUMUMAB TRIALS
por: Weisel, K., et al.
Publicado: (2022)

Daratumumab, bortezomib, cyclophosphamide and dexamethasone in newly diagnosed and relapsed multiple myeloma: LYRA study
por: Yimer, Habte, et al.
Publicado: (2019)

Subcutaneous daratumumab in patients with relapsed or refractory multiple myeloma: part 2 of the open-label, multicenter, dose-escalation phase Ib study (PAVO)
por: San-Miguel, Jesus, et al.
Publicado: (2020)

Clinical Implications of Complex Pharmacokinetics for Daratumumab Dose Regimen in Patients With Relapsed/Refractory Multiple Myeloma
por: Xu, XS, et al.
Publicado: (2017)

Pharmacokinetics of Daratumumab Following Intravenous Infusion in Relapsed or Refractory Multiple Myeloma After Prior Proteasome Inhibitor and Immunomodulatory Drug Treatment
por: Clemens, Pamela L., et al.
Publicado: (2016)

Daratumumab Improves Depth of Response and Progression-free Survival in Transplant-ineligible, High-risk, Newly Diagnosed Multiple Myeloma
por: Jakubowiak, Andrzej J, et al.
Publicado: (2022)

Efficacy and Safety of Daratumumab, Pomalidomide, and Dexamethasone (DPd) Compared to Daratumumab, Bortezomib, and Dexamethasone (DVd) in Daratumumab–Naïve Relapsed Multiple Myeloma
por: Afrough, Aimaz, et al.
Publicado: (2023)

Daratumumab plus lenalidomide and dexamethasone versus lenalidomide and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of POLLUX
por: Dimopoulos, Meletios A., et al.
Publicado: (2018)

Daratumumab Monotherapy for Relapsed or Refractory Multiple Myeloma: Results of an Early Access Treatment Protocol in Europe and Russia
por: Cook, Gordon, et al.
Publicado: (2021)

Daratumumab for the Treatment of Multiple Myeloma
por: Plesner, Torben, et al.
Publicado: (2018)

Longer term outcomes with single‐agent belantamab mafodotin in patients with relapsed or refractory multiple myeloma: 13‐month follow‐up from the pivotal DREAMM‐2 study
por: Lonial, Sagar, et al.
Publicado: (2021)

High‐Parameter Mass Cytometry Evaluation of Relapsed/Refractory Multiple Myeloma Patients Treated with Daratumumab Demonstrates Immune Modulation as a Novel Mechanism of Action
por: Adams, Homer C., et al.
Publicado: (2018)

Comparative effectiveness of ciltacabtagene autoleucel in CARTITUDE‐1 versus physician's choice of therapy in the Flatiron Health multiple myeloma cohort registry for the treatment of patients with relapsed or refractory multiple myeloma
por: Martin, Thomas, et al.
Publicado: (2021)

B06: SUBCUTANEOUS TALQUETAMAB IN COMBINATION WITH DARATUMUMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): PHASE 1B RESULTS
por: Mateos, M, et al.
Publicado: (2022)

Bortezomib-induced heat shock response protects multiple myeloma cells and is activated by heat shock factor 1 serine 326 phosphorylation
por: Shah, Shardule P., et al.
Publicado: (2016)

Dexamethasone treatment promotes Bcl-2-dependence in multiple myeloma resulting in sensitivity to Venetoclax
por: Matulis, Shannon M., et al.
Publicado: (2015)

Daratumumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of CASTOR
por: Spencer, Andrew, et al.
Publicado: (2018)

Selinexor in relapsed/refractory multiple myeloma
por: Richter, Joshua, et al.
Publicado: (2020)

Efficacy and Safety of Durvalumab Combined with Daratumumab in Daratumumab-Refractory Multiple Myeloma Patients
por: Frerichs, Kristine A., et al.
Publicado: (2021)

Daratumumab in dialysis-dependent multiple myeloma
por: Jeyaraman, Preethi, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_13l62k7vp1h3l1eimsducsm6i4